- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07373444
Westlake Aging Cohort (WeAC)
Westlake Aging Cohort
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Ju-Sheng Zheng, PhD
- Telefonnummer: 86-0571-86915303
- E-Mail: zhengjusheng@westlake.edu.cn
Studienorte
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310058
- Rekrutierung
- Hangzhou First People's Hospital
-
Kontakt:
- Ju-Sheng Zheng, PhD
- Telefonnummer: 86-0571-86915303
- E-Mail: zhengjusheng@westlake.edu.cn
-
Hangzhou, Zhejiang, China, 310058
- Rekrutierung
- Hangzhou Third People's Hospital
-
Kontakt:
- Peng Li, Master
-
Kontakt:
- Yu Chen, Master
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
All participants must be Chinese residents, regardless of their ethnicity.
Beschreibung
Inclusion Criteria:
- Age between 55 and 90 years (inclusive) at baseline.
- Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
- Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
- MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
- Healthy controls: CDR = 0, memory box = 0. MCI: CDR = 0.5, memory box ≥ 0.5. AD: CDR = 0.5 or 1. The DLB/PDD meets the core features of diagnosis.
- Healthy controls exhibit no significant cognitive or functional decline. Patients with MCI have objective cognitive impairment not sufficient for an AD diagnosis. AD patients fulfill the NINCDS-ADRDA criteria. DLB/PDD patients meet their respective international consensus diagnostic criteria. Other neurodegenerative diseases meet the diagnostic criteria.
Exclusion Criteria:
- Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
- Current use of psychoactive medications or any other drugs that may affect the study.
- Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
- Participants with any other diseases that may affect the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cognitive function
Zeitfenster: 48 months
|
Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians. |
48 months
|
|
Gut microbiome
Zeitfenster: 48 months
|
The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified. |
48 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Brain magnetic resonance imaging
Zeitfenster: 48 months
|
Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants. |
48 months
|
|
Positron emission tomography
Zeitfenster: 48 months
|
Assess the brain function and neurological disorders by positron emission tomography (PET). |
48 months
|
|
Brain images relevant inspections
Zeitfenster: 48 months
|
Other brain image relevant inspections required for study to measure brain structure and function of participants. |
48 months
|
|
Electroencephalogram
Zeitfenster: 48 months
|
Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking. |
48 months
|
|
Blood biochemical parameters
Zeitfenster: 48 months
|
Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer. |
48 months
|
|
Serum inflammatory factors
Zeitfenster: 48 months
|
Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants. |
48 months
|
|
Health and behavior monitoring
Zeitfenster: 48 months
|
Use fitness trackers to record the physiological and behavioral data of participants. |
48 months
|
|
Sleep data measurement
Zeitfenster: 48 months
|
Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality. |
48 months
|
|
Continuous glucose monitoring
Zeitfenster: 48 months
|
Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants. |
48 months
|
|
Environmental measurement
Zeitfenster: 48 months
|
Use the environmental monitoring device to measure various exposure factors in the participants' living environment. |
48 months
|
|
Multi-omics data
Zeitfenster: 48 months
|
Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc. |
48 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Ju-Sheng Zheng, PhD, Westlake University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 20251023ZJS001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .